SMYD2-dependent HSP90 methylation promotes cancer cell proliferation by regulating the chaperone complex formation

Cancer Letters

Volumn 351, Issue 1, 2014, Pages 126-133

  Hamamoto, Ryuji ^a,b   Toyokawa, Gouji ^b   Nakakido, Makoto ^a   Ueda, Koji ^c   Nakamura, Yusuke ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF TOKYO   (Japan)

^c RIKEN   (Japan)

Author keywords

HSP90; Human carcinogenesis; Non histone protein methylation; SMYD2

Indexed keywords

CHAPERONE; HEAT SHOCK PROTEIN 90; HISTONE METHYLTRANSFERASE; SMYD2 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; CELL PROLIFERATION; COMPLEX FORMATION; CONTROLLED STUDY; DIMERIZATION; DISEASE ACTIVITY; ENZYME ASSAY; HISTONE METHYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MASS SPECTROMETRY; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION;

HSP90; HUMAN CARCINOGENESIS; NON-HISTONE PROTEIN METHYLATION; SMYD2;

AMINO ACID SEQUENCE; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; HEK293 CELLS; HELA CELLS; HISTONE-LYSINE N-METHYLTRANSFERASE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; METHYLATION; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN MULTIMERIZATION; PROTEIN PROCESSING, POST-TRANSLATIONAL;

EID: 84903739596     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.05.014     Document Type: Article

References (50)

1. Trepel J., Mollapour M., Giaccone G., Neckers L. Targeting the dynamic HSP90 complex in cancer. Nat. Rev. Cancer 2010, 10:537-549.
2. Wandinger S.K., Richter K., Buchner J. The Hsp90 chaperone machinery. J. Biol. Chem. 2008, 283:18473-18477.
3. Pratt W.B., Toft D.O. Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp. Biol. Med. (Maywood) 2003, 228:111-133.
4. Whitesell L., Lindquist S.L. HSP90 and the chaperoning of cancer. Nat. Rev. Cancer 2005, 5:761-772.
5. Ogiso H., Kagi N., Matsumoto E., Nishimoto M., Arai R., Shirouzu M., Mimura J., Fujii-Kuriyama Y., Yokoyama S. Phosphorylation analysis of 90kDa heat shock protein within the cytosolic arylhydrocarbon receptor complex. Biochemistry 2004, 43:15510-15519.
6. Duval M., Le Boeuf F., Huot J., Gratton J.P. Src-mediated phosphorylation of Hsp90 in response to vascular endothelial growth factor (VEGF) is required for VEGF receptor-2 signaling to endothelial NO synthase. Mol. Biol. Cell 2007, 18:4659-4668.
7. Scroggins B.T., Robzyk K., Wang D., Marcu M.G., Tsutsumi S., Beebe K., Cotter R.J., Felts S., Toft D., Karnitz L., Rosen N., Neckers L. An acetylation site in the middle domain of Hsp90 regulates chaperone function. Mol. Cell 2007, 25:151-159.
8. Kovacs J.J., Murphy P.J., Gaillard S., Zhao X., Wu J.T., Nicchitta C.V., Yoshida M., Toft D.O., Pratt W.B., Yao T.P. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol. Cell 2005, 18:601-607.
9. Ai J., Wang Y., Dar J.A., Liu J., Liu L., Nelson J.B., Wang Z. HDAC6 regulates androgen receptor hypersensitivity and nuclear localization via modulating Hsp90 acetylation in castration-resistant prostate cancer. Mol. Endocrinol. 2009, 23:1963-1972.
10. Retzlaff M., Stahl M., Eberl H.C., Lagleder S., Beck J., Kessler H., Buchner J. Hsp90 is regulated by a switch point in the C-terminal domain. EMBO Rep. 2009, 10:1147-1153.
11. Martinez-Ruiz A., Villanueva L., Gonzalez de Orduna C., Lopez-Ferrer D., Higueras M.A., Tarin C., Rodriguez-Crespo I., Vazquez J., Lamas S. S-nitrosylation of Hsp90 promotes the inhibition of its ATPase and endothelial nitric oxide synthase regulatory activities. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:8525-8530.
12. Brown M.A., Sims R.J., Gottlieb P.D., Tucker P.W. Identification and characterization of Smyd2: a split SET/MYND domain-containing histone H3 lysine 36-specific methyltransferase that interacts with the Sin3 histone deacetylase complex. Mol. Cancer 2006, 5:26.
13. Abu-Farha M., Lambert J.P., Al-Madhoun A.S., Elisma F., Skerjanc I.S., Figeys D. The tale of two domains: proteomics and genomics analysis of SMYD2, a new histone methyltransferase. Mol. Cell. Proteomics: MCP 2008, 7:560-572.
14. Cho H.S., Hayami S., Toyokawa G., Maejima K., Yamane Y., Suzuki T., Dohmae N., Kogure M., Kang D., Neal D.E., Ponder B.A., Yamaue H., Nakamura Y., Hamamoto R. RB1 methylation by SMYD2 enhances cell cycle progression through an increase of RB1 phosphorylation. Neoplasia 2012, 14:476-486.
15. Huang J., Perez-Burgos L., Placek B.J., Sengupta R., Richter M., Dorsey J.A., Kubicek S., Opravil S., Jenuwein T., Berger S.L. Repression of p53 activity by Smyd2-mediated methylation. Nature 2006, 444:629-632.
16. Komatsu S., Imoto I., Tsuda H., Kozaki K.I., Muramatsu T., Shimada Y., Aiko S., Yoshizumi Y., Ichikawa D., Otsuji E., Inazawa J. Overexpression of SMYD2 relates to tumor cell proliferation and malignant outcome of esophageal squamous cell carcinoma. Carcinogenesis 2009, 30:1139-1146.
17. Cho H.S., Shimazu T., Toyokawa G., Daigo Y., Maehara Y., Hayami S., Ito A., Masuda K., Ikawa N., Field H.I., Tsuchiya E., Ohnuma S., Ponder B.A., Yoshida M., Nakamura Y., Hamamoto R. Enhanced HSP70 lysine methylation promotes proliferation of cancer cells through activation of aurora kinase B. Nat. Commun. 2012, 3:1072.
18. Takawa M., Cho H.S., Hayami S., Toyokawa G., Kogure M., Yamane Y., Iwai Y., Maejima K., Ueda K., Masuda A., Dohmae N., Field H.I., Tsunoda T., Kobayashi T., Akasu T., Sugiyama M., Ohnuma S.I., Atomi Y., Ponder B.A., Nakamura Y., Hamamoto R. Histone lysine methyltransferase SETD8 promotes carcinogenesis by deregulating PCNA expression. Cancer Res. 2012, 72:3217-3227.
19. Cho H.S., Suzuki T., Dohmae N., Hayami S., Unoki M., Yoshimatsu M., Toyokawa G., Takawa M., Chen T., Kurash J.K., Field H., Ponder B.A., Nakamura Y., Hamamoto R. Demethylation of RB regulator MYPT1 by histone demethylase LSD1 promotes cell cycle progression in cancer cells. Cancer Res. 2010.
20. Hayami S., Kelly J.D., Cho H.S., Yoshimatsu M., Unoki M., Tsunoda T., Field H.I., Neal D.E., Yamaue H., Ponder B.A., Nakamura Y., Hamamoto R. Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. Int. J. Cancer 2011, 128:574-586.
21. Hayami S., Yoshimatsu M., Veerakumarasivam A., Unoki M., Iwai Y., Tsunoda T., Field H.I., Kelly J.D., Neal D.E., Yamaue H., Ponder B.A., Nakamura Y., Hamamoto R. Overexpression of the JmjC histone demethylase KDM5B in human carcinogenesis: involvement in the proliferation of cancer cells through the E2F/RB pathway. Mol. Cancer 2010, 9:59.
22. Allan R.K., Mok D., Ward B.K., Ratajczak T. Modulation of chaperone function and cochaperone interaction by novobiocin in the C-terminal domain of Hsp90: evidence that coumarin antibiotics disrupt Hsp90 dimerization. J. Biol. Chem. 2006, 281:7161-7171.
23. Mollapour M., Tsutsumi S., Donnelly A.C., Beebe K., Tokita M.J., Lee M.J., Lee S., Morra G., Bourboulia D., Scroggins B.T., Colombo G., Blagg B.S., Panaretou B., Stetler-Stevenson W.G., Trepel J.B., Piper P.W., Prodromou C., Pearl L.H., Neckers L. Swe1Wee1-dependent tyrosine phosphorylation of Hsp90 regulates distinct facets of chaperone function. Mol. Cell 2010, 37:333-343.
24. Mollapour M., Tsutsumi S., Truman A.W., Xu W., Vaughan C.K., Beebe K., Konstantinova A., Vourganti S., Panaretou B., Piper P.W., Trepel J.B., Prodromou C., Pearl L.H., Neckers L. Threonine 22 phosphorylation attenuates Hsp90 interaction with cochaperones and affects its chaperone activity. Mol. Cell 2011, 41:672-681.
25. Young J.C., Agashe V.R., Siegers K., Hartl F.U. Pathways of chaperone-mediated protein folding in the cytosol. Nat. Rev. Mol. Cell Biol. 2004, 5:781-791.
26. Taipale M., Jarosz D.F., Lindquist S. HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat. Rev. Mol. Cell Biol. 2010, 11:515-528.
27. Mayer M.P. Phosphotyrosine confers client specificity to Hsp90. Mol. Cell 2010, 37:295-296.
28. Miao R.Q., Fontana J., Fulton D., Lin M.I., Harrison K.D., Sessa W.C. Dominant-negative Hsp90 reduces VEGF-stimulated nitric oxide release and migration in endothelial cells. Arterioscler. Thromb. Vasc. Biol. 2008, 28:105-111.
29. Zurawska A., Urbanski J., Matuliene J., Baraniak J., Klejman M.P., Filipek S., Matulis D., Bieganowski P. Mutations that increase both Hsp90 ATPase activity in vitro and Hsp90 drug resistance in vivo. Biochim. Biophys. Acta 1803, 2010:575-583.
30. Hamamoto R., Furukawa Y., Morita M., Iimura Y., Silva F.P., Li M., Yagyu R., Nakamura Y. SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat. Cell Biol. 2004, 6:731-740.
31. Takawa M., Masuda K., Kunizaki M., Daigo Y., Takagi K., Iwai Y., Cho H.S., Toyokawa G., Yamane Y., Maejima K., Field H.I., Kobayashi T., Akasu T., Sugiyama M., Tsuchiya E., Atomi Y., Ponder B.A., Nakamura Y., Hamamoto R. Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker. Cancer Sci. 2011.
32. Yoshimatsu M., Toyokawa G., Hayami S., Unoki M., Tsunoda T., Field H.I., Kelly J.D., Neal D.E., Maehara Y., Ponder B.A., Nakamura Y., Hamamoto R. Dysregulation of PRMT1 and PRMT6, Type I arginine methyltransferases, is involved in various types of human cancers. Int. J. Cancer 2011, 128:562-573.
33. Hamamoto R., Silva F.P., Tsuge M., Nishidate T., Katagiri T., Nakamura Y., Furukawa Y. Enhanced SMYD3 expression is essential for the growth of breast cancer cells. Cancer Sci. 2006, 97:113-118.
34. Portela A., Esteller M. Epigenetic modifications and human disease. Nat. Biotechnol. 2010, 28:1057-1068.
35. Schneider R., Bannister A.J., Kouzarides T. Unsafe SETs: histone lysine methyltransferases and cancer. Trends Biochem. Sci. 2002, 27:396-402.
36. Sparmann A., van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat. Rev. Cancer 2006, 6:846-856.
37. Esteve P.O., Chin H.G., Benner J., Feehery G.R., Samaranayake M., Horwitz G.A., Jacobsen S.E., Pradhan S. Regulation of DNMT1 stability through SET7-mediated lysine methylation in mammalian cells. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:5076-5081.
38. Guo Z., Zheng L., Xu H., Dai H., Zhou M., Pascua M.R., Chen Q.M., Shen B. Methylation of FEN1 suppresses nearby phosphorylation and facilitates PCNA binding. Nat. Chem. Biol. 2010, 6:766-773.
39. Cho H.S., Suzuki T., Dohmae N., Hayami S., Unoki M., Yoshimatsu M., Toyokawa G., Takawa M., Chen T., Kurash J.K., Field H.I., Ponder B.A., Nakamura Y., Hamamoto R. Demethylation of RB regulator MYPT1 by histone demethylase LSD1 promotes cell cycle progression in cancer cells. Cancer Res. 2011, 71:1-6.
40. Zhao R., Davey M., Hsu Y.C., Kaplanek P., Tong A., Parsons A.B., Krogan N., Cagney G., Mai D., Greenblatt J., Boone C., Emili A., Houry W.A. Navigating the chaperone network: an integrative map of physical and genetic interactions mediated by the hsp90 chaperone. Cell 2005, 120:715-727.
41. Chiosis G., Vilenchik M., Kim J., Solit D. Hsp90: the vulnerable chaperone. Drug Discov. Today 2004, 9:881-888.
42. Wayne N., Bolon D.N. Dimerization of Hsp90 is required for in vivo function. Des. Anal. Monomers Dimers J. Biol. Chem. 2007, 282:35386-35395.
43. Ali M.M., Roe S.M., Vaughan C.K., Meyer P., Panaretou B., Piper P.W., Prodromou C., Pearl L.H. Crystal structure of an Hsp90-nucleotide-p23/Sba1 closed chaperone complex. Nature 2006, 440:1013-1017.
44. Vaughan C.K., Gohlke U., Sobott F., Good V.M., Ali M.M., Prodromou C., Robinson C.V., Saibil H.R., Pearl L.H. Structure of an Hsp90-Cdc37-Cdk4 complex. Mol. Cell 2006, 23:697-707.
45. Hessling M., Richter K., Buchner J. Dissection of the ATP-induced conformational cycle of the molecular chaperone Hsp90. Nat. Struct. Mol. Biol. 2009, 16:287-293.
46. Abu-Farha M., Lanouette S., Elisma F., Tremblay V., Butson J., Figeys D., Couture J.F. Proteomic analyses of the SMYD family interactomes identify HSP90 as a novel target for SMYD2. J. Mol. Cell Biol. 2011, 3:301-308.
47. Donlin L.T., Andresen C., Just S., Rudensky E., Pappas C.T., Kruger M., Jacobs E.Y., Unger A., Zieseniss A., Dobenecker M.W., Voelkel T., Chait B.T., Gregorio C.C., Rottbauer W., Tarakhovsky A., Linke W.A. Smyd2 controls cytoplasmic lysine methylation of Hsp90 and myofilament organization. Genes Dev. 2012, 26:114-119.
48. Kamal A., Thao L., Sensintaffar J., Zhang L., Boehm M.F., Fritz L.C., Burrows F.J. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003, 425:407-410.
49. Black P.C., Agarwal P.K., Dinney C.P. Targeted therapies in bladder cancer-an update. Urol. Oncol. 2007, 25:433-438.
50. Sonpavde G., Sternberg C.N., Rosenberg J.E., Hahn N.M., Galsky M.D., Vogelzang N.J. Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium. Lancet Oncol. 2010, 11:861-870.